Jazz Pharmaceuticals PLC (JAZZ)

Debt-to-capital ratio

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Long-term debt US$ in thousands
Total stockholders’ equity US$ in thousands 4,093,760 4,171,070 3,762,600 3,696,460 3,737,000 3,489,370 3,525,680 3,335,040 3,085,730 2,745,190 3,200,780 3,608,490 3,965,190 3,938,480 4,131,490 3,797,690 3,659,740 3,377,200 3,141,800 2,808,500
Debt-to-capital ratio 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

December 31, 2024 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $4,093,760K)
= 0.00

The debt-to-capital ratio of Jazz Pharmaceuticals PLC has consistently been at 0.00 from March 31, 2020, to December 31, 2024. This indicates that the company has not utilized debt financing significantly in relation to its total capital structure over this period. A debt-to-capital ratio of 0.00 implies that the company's total debt is negligible compared to its total capital, which includes both debt and equity. This low ratio may suggest that Jazz Pharmaceuticals primarily relies on equity financing to fund its operations and growth rather than accumulating debt. Overall, a consistently low debt-to-capital ratio demonstrates strong financial health and stability in terms of managing debt obligations.